by Mathieu Ranger | 23 Mar, 2026 | Biotech Perspectives
Back to Ideas Plausible mechanism framework We are seeing a promising shift in the development and approval pathway for rare disease treatments. While small patient populations have traditionally made the evaluation of data in standard clinical trials difficult, the...
by Mathieu Ranger | 3 Feb, 2026 | Biotech Perspectives
Back to Ideas A new approach to clinical trials On January 12, the FDA shared draft guidance that may fundamentally speed up how new medicines reach patients through clinical trial analysis. Based on our reading of Pratik Pawar’s Vox article, the guidance may...
by Michelle | 31 Jan, 2026 | Biotech Perspectives
Back to Ideas Why building awareness for rare disease clinical trials matters Among the patient stories shared in the NORD 2022 Voice of the Patient Report on Post-Transplant Lymphoproliferative Disorder, one story in particular gave us pause. In it, a patient...
by Michelle | 13 Nov, 2025 | Biotech Perspectives
Back to Ideas Improving patient experience: a multidimensional measurement framework As patient experience experts, we understand this concept as multi-dimensional and extending far beyond just “treating” patients. Rather, it encompasses all interactions that a...
by Mathieu Ranger | 16 Sep, 2025 | Biotech Perspectives
Back to Ideas Lessons from the Sepsis Watch rollout This insightful article in the MIT Technology Review discusses the rollout of Sepsis Watch, a Duke Institute for Health Innovation deep-learning model designed to help emergency department (ED) doctors spot early...
by Mathieu Ranger | 1 Jun, 2025 | Biotech Perspectives
Back to Ideas Improving accessibility Today’s patients primarily engage with brands through online and digital resources. Although print still plays a role, especially in older and less tech-literate patient populations, marketing materials must be optimized for...
